^
Association details:
| Biomarker: | TIGIT overexpression |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) + Tecentriq (atezolizumab) (PD-L1 inhibitor) + Gazyva (obinutuzumab) (CD20 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A WIDE T-CELL EXHAUSTION PATTERN IS FREQUENTIN THE TUMOR MICROENVIRONMENT OF RELAPSED/REFRACTORY B-CELL LYMPHOMA PATIENTS AND COULD BE CIRCUMVENTED BY PDL1 BLOCKADE
Published date:
06/09/2021
Excerpt:
...TIGIT (>15%) was associated with better response in...R/R DLBCL (40% versus 0% of CR)...This preliminary study indicates that high expression of TIGIT in R/R DLBCL...patients are correlated with responsiveness following OBI-VEN-ATE therapy.
Trial ID:
